Marker Therapeut Stock Price, News & Analysis

Welcome to our dedicated page for Marker Therapeut news (Ticker: MRKR), a resource for investors and traders seeking the latest updates and insights on Marker Therapeut stock.

Marker Therapeutics, Inc. (Nasdaq: MRKR) is a Houston, Texas-based, clinical-stage immuno-oncology company developing multi-antigen recognizing T cell (MAR-T) therapies for hematological malignancies and solid tumors. This news page aggregates company press releases and third-party coverage related to MRKR, with a focus on clinical data, research milestones, and corporate developments.

Investors and followers of MRKR can review updates on the company’s lead program, MT-601, a MAR-T cell product being evaluated in the Phase 1 APOLLO trial for patients with relapsed or refractory lymphoma who have failed or are not candidates for anti-CD19 CAR-T cell therapy. News items include reported objective response rates, safety findings such as the absence of dose-limiting toxicities and ICANS in dose escalation cohorts, and progress into dose expansion in diffuse large B cell lymphoma.

Coverage also highlights Marker’s expansion into additional indications, including a pancreatic cancer program supported by non-dilutive funding and an Off-the-Shelf MAR-T initiative, MT-401-OTS, in the RAPID trial for relapsed acute myeloid leukemia or myelodysplastic syndromes. Readers will find announcements on first-patient dosing, early safety observations, and scientific insights such as the impact of lymphodepletion on MAR-T cell expansion and persistence.

Beyond clinical results, MRKR news includes financial updates, grant awards from U.S. state and federal agencies, collaborations such as the cGMP manufacturing agreement with Cellipont Bioservices for MT-601, participation in investor conferences, and changes in corporate governance and auditors. This page is a resource for tracking how Marker’s MAR-T platform and pipeline evolve over time.